Weiss Asset Management (WAM), a Boston-based investment firm, is seeking an Investment Compliance Analyst to join our Compliance team. This role sits at the intersection of investment compliance, trading, and data, with responsibility for monitoring trade activity, resolving compliance exceptions, and improving the systems and processes that support ongoing compliance monitoring.

Candidates graduating in Summer 2027, as well as those with 1-3 years of relevant professional experience, are encouraged to apply. Working proficiency in SQL is required; experience with Python, automation, AI tools, or order management systems is a plus. This is a full-time, in-office role based in Boston.

Responsibilities:

Monitor and resolve pre- and post-trade compliance alerts across funds and strategies, using data to spot exceptions and patterns and escalating issues with traders and internal teams as needed.
Interpret, maintain, and test trading compliance rules in the firm's order management system (OMS), and support investment-related compliance questions.
Analyze trade, position, and compliance data in SQL to support recurring reviews, reconciliations, and investigations.
Automate manual tasks with code and AI tools, building solutions that make compliance monitoring more efficient and repeatable.
Design systematic, scalable workflows for compliance reviews and escalations.
Maintain restricted securities and issuer lists across firm systems and support wall-crossing and MNPI processes.
Track regulatory developments and assess their impact on trading activity, compliance rules, policies, and procedures.
Support regulatory filings, audits, system upgrades, and ad-hoc compliance projects.

Base Salary: $85,000–$125,000 per year, depending on experience. Actual compensation will reflect the candidate's skills, relevant experience, and overall fit for the role. It is unlikely that all new hires will start at the top of this range.

About the Company:

For 34 years, Weiss Asset Management has developed proprietary investment strategies designed to deliver high risk-adjusted returns to our investors, who include charitable foundations, pension plans, endowments, hospitals, government entities and private investors. We manage approximately $4.5 billion across our hedge fund clients. We work collaboratively to solve problems, and to identify undervalued assets through deep fundamental research, statistical analysis and an analytically rigorous approach to decision making. Above all else, we value integrity, uncompromising rationality, creativity and entrepreneurship, and continuous learning and improvement.

Our team of over 140 individuals is the engine of our success, and we welcome truly exceptional candidates from all backgrounds.

WAM is a fit for you if:

You enjoy a collaborative environment, where decisions are made in diverse teams. At WAM, all employees can expect to work directly with members of other departments representing a range of backgrounds.
You work well in a flat structure and are comfortable voicing dissenting opinion. Talent and work ethic will dictate what you can achieve at WAM, as evidenced by the fact that our president and the majority of our managing directors began their careers here as interns.
You are driven to constantly learn, improve, and make rational decisions based in fact and data, and you welcome receiving feedback as well as sharing knowledge with others.
You prioritize acting ethically in all situations.

WAM is an equal opportunity employer. Women, minorities, people with disabilities, and veterans are encouraged to apply.

About the company

Weiss Asset Management manages about $2.7 billion across hedge funds and institutional accounts, using proprietary, value-based investment strategies to deliver high risk-adjusted returns for clients such as foundations, pension plans, endowments, hospitals, and government entities. The firm combines deep fundamental research, statistical analysis, and rigorous decision-making to identify undervalued assets. It differentiates itself through a collaborative problem-solving culture, a long 30-year track record, and a disciplined, rational approach guided by integrity, creativity, and continuous learning. The goal is to grow and protect client wealth by applying disciplined value investing and ongoing improvement in methods.

Company Size

51-200

Company Stage

N/A

Total Funding

N/A

Headquarters

Boston, Massachusetts

Founded

1991

Get referred to Weiss Asset Management

See people who can refer or advise you

Simplify's Take

What believers are saying

June 2026: Weiss joined BOLD in OliX's KRW 110 billion financing.
September 2026: Weiss built 10.7% of Continental Aerospace Technologies and 6.8% of RE/MAX.
Neotis and Rokit financings extend Weiss into AI hardware and healthcare in 2026.

What critics are saying

July 2026: former president sued to void Weiss noncompete, exposing retention and culture frictions.
Founder dependence stays extreme: public filings repeatedly tie decisions to Andrew M. Weiss.
A bad 2026 drawdown or redemption wave ends this partnership model; illiquid stakes amplify exits.

What makes Weiss Asset Management unique

Andrew M. Weiss still controls disclosed positions through WAM GP and Brookdale vehicles in 2026.
Weiss mixes hedge-fund capital with strategic equity stakes, from OliX to European Lithium.
Public 13G and UK Code filings show repeat, active ownership across U.S., U.K., and Asia.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours
Professional Development Budget

Company News

Benzinga

Jun 26th, 2026

Ionic Digital raises $400M at $2B valuation for AI infrastructure expansion

Ionic Digital, a digital infrastructure company supporting AI and high-performance computing, has raised $400 million in an equity private placement, implying a pre-money valuation of $2.0 billion. The round was led by Attestor, Oaktree Capital Management and Sachem Head Capital Management, with participation from Citadel and Weiss Asset Management. The Washington-based company will use the proceeds for general corporate purposes, including developing its digital infrastructure assets. Ionic Digital provides high-performance computing and data centre infrastructure designed for intensive AI workloads. J.P. Morgan and BTIG served as co-placement agents for the transaction, whilst White & Case provided legal counsel to the company.

Business Wire

Jun 4th, 2026

OliX Pharmaceuticals secures KRW 110 billion investment from BOLD, L'Oréal corporate venture capital fund, and Weiss, U.S. Hedge fund.

OliX Pharmaceuticals secures KRW 110 billion investment from BOLD, L'Oréal corporate venture capital fund, and Weiss, U.S. Hedge fund. * Participation of both strategic partner and key global investor * Underlines the potential of OliX Pharmaceuticals' siRNA platform SEOUL, South Korea-(BUSINESS WIRE)-OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that it has raised approximately KRW 110 billion through a third-party allotment of newly issued common shares to strategic investors. The investment was jointly made by BOLD, L'Oréal's corporate venture capital fund, and Weiss Asset Management LP, a U.S. asset management firm. This strategic collaboration combines OliX's world-class siRNA platform capabilities with L'Oréal's century-long commitment to beauty innovation and expertise across biology, tech, and formulation. Share BOLD is L'Oréal's venture investment arm that backs promising beauty brands, biotech, and tech companies, especially those with disruptive innovation potential. The U.S. asset manager is also a key global investor in OliX and participated in this round following its investment in August 2025. With the newly secured funds, the company intends to advance its ongoing siRNA-based projects in several therapeutic areas, including skin- and hair-related projects. The company also expects the investment to further strengthen its strategic partnership with L'Oréal. Through this, the company aims to reinforce its research foundation and accelerate development progress. Guive Balooch, Global Managing Director of Open Innovation and Augmented Beauty at L'Oréal, said, "We are excited to strengthen our scientific partnership with OliX with an equity investment by BOLD. This strategic collaboration combines OliX's world-class siRNA platform capabilities with L'Oréal's century-long commitment to beauty innovation and expertise across biology, tech, and formulation. We are convinced that together we'll accelerate in creating the future of beauty for the benefit of consumers globally with new levels of performance backed by advanced biology and robust scientific proof." Dong Ki Lee, CEO of OliX Pharmaceuticals, said, "We are delighted to secure funding from BOLD and Weiss." He added, "Their support reflects strong confidence in our partnership and shared vision for innovation. The joint participation of a global strategic partner and a major investor reflects strong market confidence in the company's technological competitiveness and future growth potential." About OliX Pharmaceuticals OliX is a biotechnology company focused on the development of innovative therapeutics that regulate disease-causing gene expression based on RNA interference (RNAi) technology. Leveraging RNAi technology, OliX is researching and developing therapeutics for a broad range of diseases, with multiple pipeline programs currently in clinical stages. OliX is developing therapeutics based on its proprietary core drug development platform, OASIS (OliX Advanced Small Interfering RNA System), which is designed to enhance the high gene-silencing efficiency of RNAi technology and enable tissue-specific delivery. Based on this platform, OliX is advancing locally administered RNAi therapeutics for various indications, including hair loss, age-related macular degeneration (AMD), and hypertrophic scars. In addition, by incorporating hepatocyte-specific delivery technology, OliX is building pipelines in liver-related diseases, including metabolic dysfunction-associated steatohepatitis (MASH), obesity, and cardiometabolic disorders. In accordance with its mid- to long-term growth strategy, the "OliX 2.0 Roadmap," OliX continues to expand the application of RNAi therapeutics. The company is building novel delivery platform technologies targeting the central nervous system (CNS) and adipose tissue, expanding its follow-on pipelines, and pursuing differentiated RNAi therapeutics across a broad range of disease areas. Contacts. OliX Pharmaceuticals, Inc. Jiyoun Kim OliX Pharmaceuticals Communications +82-31-779-8407 [email protected] More News From OliX Pharmaceuticals, Inc. SEONGNAM, South Korea-( BUSINESS WIRE )-OliX and Eli Lilly announced a global licensing agreement, focusing on the development and commercialization of OliX's OLX75016... SUWON, South Korea-( BUSINESS WIRE )-OliX Pharmaceuticals initiated patient dosing in the Phase 1 clinical trial of OLX75016 for MASH... SUWON, South Korea-( BUSINESS WIRE )-OliX Pharmaceuticals, Inc. received approval from the HREC to conduct a Phase 1 clinical trial of drug candidate OLX75016...

eDaily

May 12th, 2026

Korean precision micro-bit maker Neotis raises $213M from US hedge fund to build new factory for AI chip demand

South Korean precision micro-bit manufacturer Neotis has secured 18 billion won ($12.7 million) in strategic investment from Boston-based hedge fund Weiss Asset Management to build a new factory targeting AI semiconductor demand. The facility, scheduled to begin operations in late 2027, will expand the company's micro-bit production capacity. The investment was structured as convertible preferred shares rather than convertible bonds to minimise shareholder dilution, with 662,000 shares issued at 27,199 won each. The shares will be locked up for one year following issuance. Neotis also announced plans to cancel 140,000 treasury shares worth approximately 3.9 billion won. Founded in 2000, Neotis produces ultra-precise drill bits for printed circuit boards used in AI accelerators and semiconductor packaging, holding the leading market share in South Korea.

eDaily

Mar 10th, 2026

Rokit Healthcare raises $45M from global investors including Weiss Asset Management

Rokit Healthcare has raised 62.5 billion won (approximately $45 million) in a Series funding round, with foreign capital accounting for 72% of the total investment. Leading investors include Weiss Asset Management (30 billion won), Oasis Management (7 billion won), Pacific Alliance Group (5 billion won), and LMR (3 billion won). Domestic investors, including NH Investment & Securities, Asem, Anda, GVA, and Milestone Asset Management, contributed 17.5 billion won. The investment, structured as redeemable convertible preferred shares with a one-year lock-up period, aims to minimise short-term share price volatility. The South Korean biotech and regenerative medicine company said the funding marks a turning point in its journey towards becoming a global leader in the sector.

Business Wire

Dec 20th, 2025

Orum Therapeutics Secures Approximately US$100 Million to Accelerate Development of Leading Degrader Antibody Conjugate Programs to Treat Serious Diseases

Orum Therapeutics (“Orum” or the “Company”) (KRX: 475830), a public biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today ...

Weiss Asset Management

Investment Compliance Analyst - Trading Systems

About the job